Among the many clinical trials assessing HER2-targeted strategies in advanced GC, only a few—namely the ToGA trial, KEYNOTE-811, and DESTINY-Gastric01/02—have demonstrated statistically and clinically meaningful results. The gene discussed is ERBB2; the disease is gastric cancer.